Last checked at 24 Oct 2022 07:00
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Shield Presents Data at ACG Annual Scientific Meeting 2022 on Accrufer®
London, UK, 24 October 2022: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), announces that a pooled analysis from ferric maltol clinical trials will be presented at the American College of Gastroenterology Annual Scientific Meeting (ACG 2022). ACG 2022 is underway, virtually and in-person, and runs through to 26 October 2022 in Charlotte, North Carolina, USA.
The abstract is available online in the ACG 2022 Abstract Guide: https://acgmeetings.gi.org/
Shield Therapeutics Poster Presentation Details:
Poster: | D0361 |
Title: | "A pooled analysis of early and sustained response in patients with Inflammatory Bowel Disease (IBD) with Iron Deficiency Anemia (IDA) who were treated with ferric maltol" |
Date: | 25 October 2022 |
Time: | 10:00AM - 12:00PM ET |
ACG 2022 is one of the most prestigious gastrointestinal (GI) clinical conferences, bringing together GI physicians and providing them with the opportunity to network with peers, share experiences from their practice, learn the latest clinical information on key GI topics, and see the latest advances in GI technology and therapeutics throughout the conference.
For further information please contact:
Shield Therapeutics plc | www.shieldtherapeutics.com |
Greg Madison, CEO | +44 (0) 191 511 8500 |
Hans-Peter Rudolf, CFO |
|
Nominated Adviser and Joint Broker |
|
Peel Hunt LLP |
|
James Steel/Christopher Golden | +44 (0)20 7418 8900 |
Joint Broker finnCap Ltd Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks |
+44 (0)20 7220 0500 |
|
|
Financial PR & IR Advisor |
|
Walbrook PR |
|
Lianne Applegarth/Alice Woodings | +44 (0)20 7933 8780 or shield@walbrookpr.com |
| |
Investor Contact (US Advisor) LifeSci Advisors, LLC John Mullaly |
+1 617 429 3548 or jmullaly@lifesciadvisors.com |
About Accrufer®/Feraccru®
Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of action compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.
Accrufer®/Feraccru® has patent coverage until the mid-2030s
Accrufer®/Feraccru® are registered trademarks of the Shield Group